论文部分内容阅读
目的:探讨2型糖尿病合并慢性阻塞性肺疾病患者血清瘦素水平的变化及其临床意义。方法:收集110例患者信息,受试对象严格按入选标准入组,分为健康对照组10例、单纯慢性阻塞性肺疾病急性发病期(AECOPD)组、单纯COPD稳定期组、单纯2型糖尿病(T2DM)组、AECOPD期合并T2DM组,COPD合并T2DM组,每组各20例;采用酶联免疫测定法(ELISA)检测各组血清瘦素和IL-6的含量。结果:患者血清中瘦素水平比较:COPD稳定期组低于其它各组(P<0.05);AECOPD低于T2DM+AECOPD组(P<0.05),高于对照组(P<0.05),与T2DM组差异无统计学意义(P>0.05);T2DM+COPD组与对照组差异无统计学意义(P>0.05),高于COPD组(P<0.05);T2DM+AECOPD组高于对照组(P<0.01)、AECOPD组(P<0.05)及T2DM组(P<0.05);T2DM组高于对照组(P<0.05)。患者血清中IL-6水平比较:各组均高于对照组(P<0.05);COPD组与T2DM差异无统计学意义(P>0.05),低于其它各组(P<0.05);AECOPD组低于T2DM+AECOPD组(P<0.05),与T2DM组差异无统计学意义(P>0.05);T2DM+COPD组高于COPD组(P<0.05);T2DM+AECOPD组高于AECOPD组(P<0.05)。结论:患者瘦素与IL-6含量可作为T2DM合并COPD患者的临床治疗及检测的指标。
Objective: To investigate the changes and clinical significance of serum leptin in type 2 diabetes mellitus patients with chronic obstructive pulmonary disease. Methods: The information of 110 patients was collected. The subjects were randomly divided into the control group and the control group. The subjects were divided into healthy control group (n = 10), acute phase of chronic obstructive pulmonary disease (AECOPD) group, stable COPD group, simple type 2 diabetes mellitus (T2DM), AECOPD with T2DM, and COPD with T2DM (20 in each group). Serum leptin and IL-6 levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: Compared with control group (P <0.05), leptin level in patients with COPD was lower than those in other groups (P <0.05), AECOPD was lower than that in T2DM + AECOPD group (P <0.05) (P> 0.05). There was no significant difference between T2DM + COPD group and control group (P> 0.05), but higher than that of COPD group (P <0.05) <0.01), AECOPD group (P <0.05) and T2DM group (P <0.05), T2DM group was higher than that of control group (P <0.05). The level of IL-6 in serum of patients was significantly higher than that of control group (P <0.05), but there was no significant difference between COPD group and T2DM group (P> 0.05) (P <0.05); T2DM + COPD group was higher than COPD group (P <0.05); T2DM + AECOPD group was higher than AECOPD group (P <0.05) <0.05). Conclusion: The levels of leptin and IL-6 in patients with T2DM can be used as an index of clinical treatment and detection in patients with T2DM and COPD.